Evidence map›Paper›PMID 23399358›Full record

ArticleBlood transfusion = Trasfusione del sangue2014

The plasma levels of soluble HLA-G molecules correlate directly with CD34+ cell concentration and HLA-G 14bp insertion/insertion polymorphism in cord blood donors.

Cristina Capittini, Paola Bergamaschi, Sara Sachetto, Mariarosa Truglio, Monica Viola, Andrea Marchesi, Valeria Genovese, Bina Romano, Marco Guarene, Rossella Poma and 3 more

Abstract readComparative Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Blood transfusion = Trasfusione del sangue, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed, 1 pooled it
0.4field-weighted citation impact, top 40% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 1 synthesis or guideline pooled it, 7 citations in OpenAlex.

  1. Pooled it
  2. Endothelial Progenitor Cell CD34Reproductive sciences (Thousand Oaks, Calif.) · 2021
    Article
  3. HLA-G Neo-Expression on Tumors.Frontiers in immunology · 2020
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 1 institution in 1 country.

Cristina CapittiniImmunogenetics Laboratory, Immunohaematology and Transfusion Medicine Department, IRCCS Policlinico San Matteo Foundation, Pavia, Italy.
Paola BergamaschiPavia Cord Blood Bank, Immunohaematology and Transfusion Medicine Department, IRCCS Policlinico San Matteo Foundation, Pavia, Italy.
Sara SachettoSerological and Molecular Diagnostics Laboratory, Immunohaematology and Transfusion Medicine Department, IRCCS Policlinico San Matteo Foundation, Pavia, Italy.
Mariarosa TruglioSerological and Molecular Diagnostics Laboratory, Immunohaematology and Transfusion Medicine Department, IRCCS Policlinico San Matteo Foundation, Pavia, Italy.
Monica ViolaSerological and Molecular Diagnostics Laboratory, Immunohaematology and Transfusion Medicine Department, IRCCS Policlinico San Matteo Foundation, Pavia, Italy.
Andrea MarchesiPavia Cord Blood Bank, Immunohaematology and Transfusion Medicine Department, IRCCS Policlinico San Matteo Foundation, Pavia, Italy.
Valeria GenovesePavia Cord Blood Bank, Immunohaematology and Transfusion Medicine Department, IRCCS Policlinico San Matteo Foundation, Pavia, Italy.
Bina RomanoPavia Cord Blood Bank, Immunohaematology and Transfusion Medicine Department, IRCCS Policlinico San Matteo Foundation, Pavia, Italy.
Marco GuareneImmunogenetics Laboratory, Immunohaematology and Transfusion Medicine Department, IRCCS Policlinico San Matteo Foundation, Pavia, Italy.
Rossella PomaSerological and Molecular Diagnostics Laboratory, Immunohaematology and Transfusion Medicine Department, IRCCS Policlinico San Matteo Foundation, Pavia, Italy.
Miryam MartinettiImmunogenetics Laboratory, Immunohaematology and Transfusion Medicine Department, IRCCS Policlinico San Matteo Foundation, Pavia, Italy.
Carmine TinelliClinical Epidemiology and Biometric Unit, IRCCS Policlinico San Matteo Foundation, Pavia, Italy.
Laura SalvaneschiPavia Cord Blood Bank, Immunohaematology and Transfusion Medicine Department, IRCCS Policlinico San Matteo Foundation, Pavia, Italy.
Policlinico San Matteo Fondazione · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundCord blood provides haematopoietic stem cells for allogeneic transplantation and, thanks to the naivety of its immune system, has several advantages over other sources of stem cells. In the transplantation setting, the presence of immunosuppressive human leucocyte antigen (HLA)-G molecules has been advocated to prevent both rejection and Graft-versus-Host disease. HLA-G is physiologically expressed throughout pregnancy and is contained in cord blood at birth. Moreover, it has recently been reported that not only cord blood mesenchymal cells, but also CD34+ cell progenies produce soluble HLA-G (sHLA-G). We tried to identify the largest producer of sHLA-G among 85 healthy cord blood donors at Pavia Cord Blood Bank, correlating the sHLA-G concentration with the HLA-G 14bp insertion/deletion (INS/DEL) genotype and CD34+ cell concentration. MATERIALS AND

methodsWe measured sHLA-G levels in 36 cord blood plasma stored at -20 °C for 2 months and 49 cord blood plasma stored at -196 °C for 4-6 years, by enzyme-linked immunosorbent assay. All cord blood donors were genotyped for the HLA-G 14bp INS/DEL polymorphism by polymerase chain reaction. For each cord blood unit, we measured the cell concentration by flow cytometry.

resultsWe did not find differences in sHLA-G levels between cord blood plasma aliquots stored for 4-6 years at -196 °C and cord blood plasma aliquots stored for 2 months at -20 °C. We observed a higher sHLA-G concentration in cord blood plasma donors who carried the HLA-G 14bp INS/INS genotype and had higher CD34+ cell concentrations (P=0.006). DISCUSSION: This is the first report showing that the best cord blood stem cell donor is also the best sHLA-G producer, particularly if genetically characterized by the HLA-G 14bp INS/INS genotype. If the therapeutic role of sHLA-G molecules were to be finally established in the transplantation setting, our data suggest that cord blood plasma donors can provide a safe source of allogeneic sHLA-G immunosuppressive molecules ready for transfusion.

Indexed as

Blood Cell CountBlood DonorsHematopoietic Stem CellsMutagenesis, InsertionalPolymorphism, Single Nucleotide3' Untranslated RegionsAntigens, CD34ExonsFemaleGenotyping TechniquesHLA-G AntigensHumansINDEL MutationInfant, NewbornMalePolymerase Chain Reaction3' Untranslated RegionsAntigens, CD34HLA-G Antigens

Identifiers

PMID23399358
PMCPMC3934295
OpenAlexW129104614

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.